Mindfulness is a simple form of meditation that allows people to really live in the moment, to be aware and attentive during everyday activities. Studies suggest that this can help physicians provide better care for their patients and help them to avoid burnout.
The PEPPER trial is investigating which blood thinner is best for patients to use after total hip and knee replacement surgery to prevent blood clots. Researchers are currently looking to enroll 25,000 patients across 25 sites in North America. To learn more and to find out if the trial is recruiting near you, visit the PEPPER trial's website. If you would like to participate, please contact the program manager, Carol Lambourne at 843-792-2913 or firstname.lastname@example.org.
Sign up to recieve our quarterly print newsletter, The Beat.
Dedicated to providing patients and healthcare providers with the information they need to combat thrombosis, The Beat features a wide range of articles, including updates on ground breaking research being done in the field of thrombosis, patient profiles, heart healthy tips from medical experts, healthy recipes specifically chosen for patients with thrombosis, and updates on the ever-growing programs that NATF puts on throughout the year. Readers get a first-hand look at NATF’s upcoming events and initiatives.
In addition, The Beat also features an “Ask the Expert” section where thrombosis specialists address questions from patients, covering topics that range aneurysms of the aorta to blood clot formation.
April 20-22, 2017
Los Angeles, CA
Early Bird Registration Ends December 15
3-Day symposium will bring together medical professionals in fields ranging from cardiology and hematology to pharmacy and family medicine for discussions on current research and evidence-based practices in the field of antithrombotic therapy. In addition to presentations by leading experts, the conference will feature small, topic-specific master classes, a "meet the expert" breakfast, poster sessions and industry exhibits.
For more information and to register, visit acforum2017.org
For this program, entitled 'Pushing the Envelope in Cardiovascular Disease Prevention: Novel Risk Factors, New Therapies, and One Brave Idea', four experts in the field of Thrombosis Medicine will share updates including innovative ways to prevent and treat diabetes and metabolic syndrome, whether a simple blood test can predict your risk of developing cardiovascular disease, new medications to lower cholesterol, and a glimpse into the largest ever research project to cure heart disease.
Offering patients the chance to ask questions, share common concerns, support one another, and learn up-to-date and accurate information about VTE. In upcoming months, we will have alternating physicians serving as moderators for group, each with their own perspective.
Upcoming Support Group Dates: March 8 at 7pm with Dr. Susan Kahn
SIGN UP NOW to receive information on how to join a support group.
Cholesterol is a type of fat found in the body. It plays a key role in how the body functions, but it can also be harmful if there is too much of it. – See More
In addition to helping patients with health issues related to high cholesterol, statins may also help guard against venous thromboembolism (VTE), which includes deep vein thrombosis (DVT) and pulmonary embolism (PE). – See More
The Acute Venous Thrombosis: Thrombus Removal with Adjunctive Catheter-Directed Thrombolysis (ATTRACT) trial is designed to test how effective pharmacomechanical catheter-directed thrombolysis (PCDT) is at preventing post-thrombotic syndrome. – See More
Did you miss our January online support group? You can still see a recording of Dr. Geoffrey Barnes, a cardiologist and vascular medicine specialist at the University of Michigan Health System, discussing shared decision making. – See More
For many years, Warfarin was the only oral anticoagulant commonly used to treat blood clots. In the past five years, the FDA has approved four new oral anticoagulants for the treatment of DVT, PE, and SPAF. Find out the differences between the five FDA-approved oral anticoagulants. View the Chart.